Skip to main content
. 2012 Jun;75(6):633–640. doi: 10.1111/j.1365-3083.2012.02694.x

Figure 3.

Figure 3

(A) Comparison of BAFF levels in the cerebrospinal fluid (CSF) and clinical subsets of Neuro-Behçet's disease (NBD). CSF BAFF levels were significantly higher in patients with a chronic course (n = 8) compared with those with an acute course (n = 10), (mean ± SD, 10.2 ± 4.0 ng/ml; median, 10.4 ng/ml versus mean ± SD, 3.9 ± 4.2 ng/ml; median, 2.7 ng/ml, P = 0.015). (B) CSF IL-6 levels were not significantly different between patients with a chronic course and those with an acute course (mean ± SD, 31.5 ± 86.0 pg/ml; median, 1.0 pg/ml versus mean ± SD, 16.2 ± 26.7 pg/ml; median, 1.1, P = 0.65). (C) Of 18 patients with NBD, 14 (eight patients with a chronic course and six patients with an acute course), paired CSF samples were obtained before and after therapy. In NBD patients with a chronic course (n = 8), BAFF levels significantly decreased from mean ± SD of 10.2 ± 4.0 ng/ml and median of 10.4 ng/ml to 6.2 ± 3.6 ng/ml and 5.9 ng/ml after therapy, respectively (P = 0.012, Wilcoxon's test). Of six of NBD patients with an acute course whose sera were available, BAFF levels at diagnosis were not different from those after therapy (mean ± SD, 3.5 ± 5.2 ng/ml; median, 0.3 ng/ml versus mean ± SD, 3.5 ± 4.9 ng/ml; median, 0.3 ng/ml). (D) Changes in CSF IL-6 levels before and after therapy. There was no difference in CSF IL-6 levels between time of diagnosis and after therapy, both in patients with an acute course (mean ± SD, 23.0 ± 32.9 pg/ml; median, 7.9 pg/ml at diagnosis and mean ± SD, 1.5 ± 0.9 pg/ml; median, 1.1 pg/ml after therapy) and in patients with a chronic course (from mean ± SD, 1.2 ± 0.6 pg/ml; median, 1.0 pg/ml at diagnosis to 1.1 ± 0.5 and 1.0 pg/ml after therapy).